DAVAL INTERNATIONAL LIMITED is an emerging life sciences company focused on the development and delivery of a novel treatment for serious unmet medical needs through a combination of innovation, dedication, entrepreneurship, skilled science and partnership. From its inception in 2000, the founder and management team of Daval have had a vision of bringing effective treatments that noticeably improve the quality of life of patients suffering from the most serious debilitating neuro-degenerative, inflammatory and autoimmune diseases and to offer a choice over and above some of the disease modifying treatments currently available.
Daval’s lead product candidate for human medication is AIMSPRO®, a drug derived by raising hyperimmune caprine serum against an inactivated HIV IIIB viral lysate. AIMSPRO is now nearing the completion of “proof of concept” stage clinical development trials for the treatment of Established Diffuse Cutaneous Systemic Sclerosis (Scleroderma) and for Secondary Progressive Multiple Sclerosis (SPMS). Other disease indications are under active investigation.
Ceremben® is the veterinary equivalent of AIMSPRO that has a Minor Use permit from the Australian Pesticides and Veterinary Medicines Authority (APVMA) for the treatment of endotoxaemia in horses, which enables the sale of Ceremben to Veterinary Surgeons in Australia.
Daval was accepted as a member of the UK’s Association of the British Pharmaceutical Industry (ABPI) in December 2007 and adheres to the APBI's Code of Practice. Daval has also recently joined Pennsylvania BIO.